Goldman Sachs Maintains Buy on Amylyx Pharma, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a Buy rating on Amylyx Pharmaceuticals (NASDAQ: AMLX) but reduced the price target from $46 to $40. This adjustment reflects a change in valuation while still indicating a positive outlook on the company's stock.
November 10, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has reaffirmed its Buy rating on Amylyx Pharmaceuticals but lowered the price target, suggesting confidence in the company's prospects albeit with a more conservative valuation.
The reduction in price target by a prominent analyst could lead to a short-term negative sentiment as it implies a lower expected future stock price. However, maintaining a Buy rating indicates a continued positive long-term outlook, which could balance the short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100